Current trends in multiple myeloma management

Journal of International Medical Research

Volumn 36, Issue 3, 2008, Pages 371-386

  Redzepovic, Jasmina ^a   Weinmann, G ^b   Ott, I ^a   Gust, R ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BAYER AG   (Germany)

Author keywords

Arsenic trioxide; Bisphosphonates; Bortezomib; Lenalidomide; Myeloma; Thalidomide; Tipifarnib

Indexed keywords

ALBUMIN; ALENDRONIC ACID; ALPHA2B INTERFERON; ARSENIC TRIOXIDE; ASCORBIC ACID; BETA 2 MICROGLOBULIN; BORTEZOMIB; CALCIUM; CARMUSTINE; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETIDRONIC ACID; ETOPOSIDE; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; LIPOSOME; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; RISEDRONIC ACID; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE LESION; BONE MARROW DISEASE; BONE NECROSIS; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHILL; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEALTH CARE ORGANIZATION; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; INHIBITION KINETICS; INJECTION SITE REACTION; KIDNEY DISEASE; KIDNEY FAILURE; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASIA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; STEM CELL EXPANSION; SUDDEN DEATH; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

EID: 45149123364     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600301     Document Type: Review

References (111)

1. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
2. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
3. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
4. Smith A, Wisloff F, Samson D: Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2006; 132: 410-451.
5. Parkin DM, Bray F, Ferlay et al: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
6. Kamangor F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
7. Baris D, Brown LM, Silverman DT, et al: Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health 2000; 90: 1277-1281.
8. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
9. Schottenfeld D, Fraumeni JF Jr (eds): Cancer Epidemiology and Prevention, 2nd edn. Oxford: Oxford University Press, 1996; pp 946-970.
10. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment of multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
11. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 1983; 308: 314-316.
12. Hjorth M, Hellquist L, Holmberg E, et al on behalf of the Myeloma Group of Western Sweden: Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study. Eur J Haematol 1993; 50: 95-102.
13. Riccardi A, Mora O, Tinelli C, et al on behalf of the Cooperative Group of Study and Treatment of Multiple Myeloma: Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Br J Cancer 2000; 82: 1254-1260.
14. Cuzick J: Radiation-induced myelomatosis. N Engl J Med 1981; 304: 204-210.
15. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342.
16. Katzel JA: Multiple myetoma; charging toward a bright future. CA Cancer J Clin 2007; 57: 301-318.
17. Alexanian R, Barlogie B, Dixon D: High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11.
18. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
19. Manconduit M, Le Loet X, Bernard JF, et al: Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory of relapsing multiple myeloma. Br J Haematol 1986; 63: 599-601.
20. Facon T, Mary JY, Pégourie B, et al: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292-1298.
21. Berenson JR: The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Rev Contemp Pharmacother 1998; 9: 195-203.
22. Fleisch H: Bisphosphonates in Bone Disease: from the Laboratory to the Patient, 3rd edn. New York: Parthenon Publishing Group, 1997; pp 1-184.
23. Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696.
24. Elomma I, Blomqvist C, Porkka L, et al: Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987; 8(suppl 1): S53-S56.
25. Martoni A, Guaraldi M, Camera P, et al: Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 1991; 48: 97-101.
26. Hortobagyi GN, Theriault RL, Porter L, et al on behalf of the Protocol 19 Aredia Breast Cancer Study Group: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-1791.
27. Djulbegovic B, Wheatley K, Ross J, et al: Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; CD003188.
28. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
29. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
30. Durie BGM, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
31. Bagan JV, Murillo J, Jimenez Y, et al: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-123.
32. Woo SB, Hellstein JW, Kalmor JR, et al: Narrative [corrected] review: bisphosphonates and osteonecrosis of the laws. Ann Intern Med 2006; 144: 753-761.
33. Zervas K, Verrou E, Teleioudis Z, et al: Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006, 134: 620-623.
34. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968-971.
35. Badros A, Weikel D, Salama A, et al: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945-952.
36. Bross PF, Kane R, Farrell AT, et al: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10: 3954-3964.
37. Richardson P, Sonneveld P, Schuster M, et al: Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study. Blood 2004; 104: 1479 [ASH Annual Meeting Abstract].
38. Richardson P, Sonneveld P, Schuster M, et al: Bortezomib continues demonstrates superior efficacy compared with high-dose dexomethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood 2005; 106: 2547 [ASH Annual Meeting Abstract].
39. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
40. Thomas DA, Kantarjian HM: Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 564-573.
41. Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-2602.
42. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
43. Juliusson G, Celsing F, Turesson J, et al: Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
44. Barlogie B, Desikon R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
45. Dimopoulos MA, Zervas K, Kouvatseas G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
46. Glasmacher A, Hahn C, Hoffmann F, et al: A systematic review of phase-Il trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584-593.
47. Ludwig H, Drach J, Tóthová E, et al: Thalidomide-dexamethasone versus melphalan-prednisone as first line treatment in elderly patients with multiple myeloma: an interim analysis. Blood 2005; 106: 782 [ASH Annual Meeting Abstract].
48. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
49. Dimopoulos MA, Zervas K, Kouvotseas G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
50. Facon T, Mary J, Harousseau J, et al: Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 2006; 24(suppl): 1 [ASCO Annual Meeting Abstract].
51. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831.
52. Cavenagh JD, Oakervee H, UK Myeloma Forum and the BCSH Haematology/ Oncology Task Forces: Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18-26.
53. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
54. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96: 2943-2950.
55. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322.
56. Anderson KC: The role of immunomodulatory drugs in multiple myeloma. Semin Hematol 2003; 40: 23-32.
57. Muller GW, Chen R, Huang SY, et al: Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production. Bioorg Med Chem Lett 1999; 9: 1625-1630.
58. Lentzsch S, LeBlanc R, Podor K, et al: Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41-44.
59. Mitsiades N, Mitsiades CS, Poulaki V, et al: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530.
60. Teo SK: Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005; 7: E14-E19.
61. Bartlett JB, Tozer A, Stirling D, et al: Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. Br J Cancer 2005; 93: 613-619.
62. Richardson P, Jagannath S, Hussein M, et al: A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood 2005; 106: 1565 [abstract].
63. Rajkumar SV, Hayman S, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 781 [abstract].
64. Weber DM, Chen C, Niesvizky R, et al: Lenolidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). J Clin Oncol 2006; 24(suppl): 7521 [ASCO Annual Meeting Abstract].
65. Dimopoulos MA, Spencer A, Attal M, et al: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood 2005; 106: 6 [ASH Annual Meeting Abstract].
66. Richardson PG, Blood E, Mitsiades CS, et al: Randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-3464.
67. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654.
68. Lowy DR, Willumsen BM: Function and regulation of RAS. Annu Rev Biochem 1993; 62: 851-891.
69. Hayashi T, Hideshima T, Akiyama M, et al: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860.
70. Kohl NE, Mosser SD, deSolms SJ, et al: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260: 1934-1937.
71. End DW, Smets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-137.
72. Mesa RA: Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther 2006; 6: 313-319.
73. Alsina M, Fonseca R, Wilson EF, et al: Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103: 3271-3277.
74. Kaufman JL, David E, Torre C, et al: Enhanced levels of apoptosis by combination of farnesyl transferase inhibition (tipifarnib) and proteasome inhibition (bortezomib) in myeloma cell lines and primary myeloma cells and its mechanistic effects on Akt and caspase pathways. Blood 2005; 106: 1573 [ASH Annual Meeting Abstract].
75. Krammer PH: CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
76. Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 2004; 116: 205-219.
77. Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998; 281: 1312-1316.
78. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.
79. Nicholson DW: Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999; 6: 1028-1042.
80. Lavrik IN, Golks A, Krammer PH: Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2665-2672.
81. Jiang X, Wang X: Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem 2000; 275: 31199-31203.
82. Korsmeyer SJ, Wei MC, Saito M, et al: Proapoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-1173.
83. Liu Q, Hilsenbeck S, Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101: 4078- 4087.
84. Munshi NC, Tricot G, Desikan R, et al: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16: 1835-1837.
85. Hussein MA, Saleh M, Ravandi F, et al: Phase 2 study of arsenic trioxide in patients with relapsed or refractor multiple myeloma. Br J Haematol 2004; 125: 470-476.
86. Douer D, Tallman MS: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396-2410.
87. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658-3668.
88. Westervelt P, Brown RA, Adkins DR, et al: Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-271.
89. Unnikrishnan D, Dutcher JP, Varshneya N, et al: Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-1516.
90. Berenson JR, Boccia R, Siegel D, et al: Efficacy and safety of melpha0lan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006; 135: 174-183.
91. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424-436.
92. Rifkin RM, Gregory SA, Mohrbacher A, et al: Pegylated liposomal doxorubicin, vincristine, and dexomethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006; 106: 848-858.
93. Dimopoulos MA, Pouli A, Zervas K, et al: Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14: 1039-1044.
94. Galanski M, Jakupec MA, Keppler BK: Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem 2005; 12: 2075-2094.
95. Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10: 1663-1682 [review].
96. Ott I, Gust R: Special qualities of inorganic cytostatics. Medicinal chemistry of platinum complexes. Pharm Unserer Zeit 2006; 35: 124-133 [in German].
97. Corso A, Mangiacavalli S, Nosari A, et al: Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 2005; 36: 951-954.
98. Corso A, Arcaini L, Caberlon S, et al: A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002; 87: 1041-1045.
99. Lazzarino M, Corso A, Barbarano L, et al: DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28: 835-839.
100. Gojo I, Meisenberg B, Guo C, et al: Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 65-72.
101. Barlogie B: High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Haematol 2001; 38: 21-27.
102. D'Sa S, Yong K, Kyriakou C, et al: Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. Br J Haematol 2004; 125: 756-765.
103. Lee CK, Barlogie B, Munshi N, et al: DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732-2739.
104. Offidani M, Mele A, Corvatta L, et al: Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma. Leuk Lymphoma 2002; 43: 1273-1279.
105. Alas S, Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326.
106. Harrouseau JL, Greil R, Kloke O, et al: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol 2005; 16(suppl 1): 45-47.
107. Smith A, Wisloff F, Samson D, et al: Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132: 410-451.
108. Barosi G, Boccadoro M, Cavo M, et al: Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004; 89: 717-741.
109. Durie BG, Kyle RA, Belch A, et al: Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology J 2003; 4: 379-398.
110. Traynor AE, Noga SJ, NCCN Multiple Myeloma Practice Guidelines Panel: NCCN: Multiple myeloma. Cancer Control 2001; 8(6 suppl 2): 78-87.
111. Imrie K, Esmail R, Meyer RM, et al: The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Int Med 2002; 136: 619-629.